Immunotherapeutic potential of oncolytic vaccinia virus. - Wikidata - wikimedia - TriplyDB

Immunotherapeutic potential of oncolytic vaccinia virus.

Immunotherapeutic potential of oncolytic vaccinia virus.

http://www.wikidata.org/entity/Q37895969

about

Effective oncolytic vaccinia therapy for human sarcomas.Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI)Progress of oncolytic viruses in sarcomas.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Oncolytic viruses in the treatment of cancer: a review of current strategies.Advance in herpes simplex viruses for cancer therapy.Immunotherapeutic potential of oncolytic vaccinia virus.ΔPK oncolytic activity includes modulation of the tumour cell milieu.An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites.Theranostic potential of oncolytic vaccinia virus.Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.Functional insights into pathogen biology from 3D electron microscopy.Oncolytic Virotherapy and the Tumor Microenvironment.

P2860

Q35954052-FECFFB50-6839-4115-9848-5FE75A8C9016 Q36378248-57EF3D30-DB0C-43BB-AB1C-E7CC4297EB05 Q36456487-90353386-2944-4144-A909-FFA28672CFC5 Q36520695-D0F7957B-C9ED-4E8C-82A6-D52BBB6B1AC8 Q36562901-131ECFCD-662E-4BC0-AAB7-12E1895B9E9A Q36618327-5A2B0564-AE69-4EC2-A5BF-6224867995B7 Q37982449-19C420B1-04E6-4CF0-BE79-D1B9E452FEAA Q38008023-6F2988CD-3446-4B75-8E50-183A72C9F9BA Q38020107-D3284FA6-D456-4716-A493-BD8A85FAD4F4 Q38096940-BC544DDF-4297-4EB8-83BF-A931822ACC2A Q38225561-D4FB3DD8-8131-4EEB-85F2-82023618DA32 Q38817112-5E541C42-CD3C-4AB5-8D48-E3DC284A2912 Q38933648-7A095B61-9AEE-4E21-BDAF-12269C4A23FF Q39628429-BC0B7FBD-08A6-45B3-85A2-A81BE440E4EC Q40162348-47BE2C90-C301-4734-9991-CA82C3CC51CD Q41596217-A5DAC208-1A74-4D48-A1ED-4586F919E34A Q47560690-C9FA01DA-791C-4AD2-8117-8F3014B4AF51

P2860

Immunotherapeutic potential of oncolytic vaccinia virus.

http://www.wikidata.org/entity/Q37895969

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunotherapeutic potential of oncolytic vaccinia virus.

@en

Immunotherapeutic potential of oncolytic vaccinia virus.

@nl

type

label

Immunotherapeutic potential of oncolytic vaccinia virus.

@en

Immunotherapeutic potential of oncolytic vaccinia virus.

@nl

prefLabel

Immunotherapeutic potential of oncolytic vaccinia virus.

@en

Immunotherapeutic potential of oncolytic vaccinia virus.

@nl

P1433

Q37895969-D401E956-8C95-44D5-ACB6-34EC82BAE73F

P1476

Q37895969-0994EED1-BAC9-4CB0-961B-074FBCDDE95F

P2093

Q37895969-D794C5A1-CDC1-4A0D-BF28-53528625D576

P2860

Q37895969-07208790-4F9C-4465-A66F-E411635F36BC

Q37895969-0CCF5F85-E13D-4D1A-BB3A-A52604D4A25F

Q37895969-17318C60-0DA2-4C57-9543-C90D7B792C18

Q37895969-19240B00-C203-4EE1-BC02-DFC6D5363660

Q37895969-1A9B4F0D-C5E1-4B6F-BCC1-1BDCEA69A90B

Q37895969-1E29D4BB-DA9C-4357-9FF7-6E0C230DF8E2

Q37895969-1E436C2F-2990-4AC7-A0C8-2AB3E0C39CE8

Q37895969-1F3E55A7-D750-48FA-B973-7E726FA41E22

Q37895969-26A8478D-7C61-47EB-88A6-72982903DDEC

Q37895969-273D6AE1-5132-48F9-A8F1-2933591F4594

P2888

Q37895969-53F5D9D9-7FF6-448C-8353-37F9621A046F

P304

Q37895969-C4F418FB-4A6E-4A8B-864C-692E2D4AED84

P31

Q37895969-21138ADB-B52E-4A7F-9FB9-3A88AA13BA2D

P356

Q37895969-58D11FB1-7DBC-486D-84A4-1CCA99244572

P433

Q37895969-358A1D0F-FFAF-4EB9-AE10-3DD9A64ABA35

P478

Q37895969-CB1BCC7D-2B92-4E15-85DA-FE99D6543551

P577

Q37895969-14AB861A-D675-4423-926B-C3A7FD772F4A

P5875

Q37895969-361D3C15-73F2-4E2C-8DEB-4A7F8516A70F

P698

Q37895969-A3A621AE-31DC-4237-BF95-280617D5FDA6

P921

Q37895969-03DA8CF2-F45E-4E35-AE44-C69982D53916

Q37895969-CDCE8F96-CE5D-46B1-B6BA-3AB45BFEF3AD

P356

S12026-011-8211-4

P1433

Immunologic Research

P1476

Immunotherapeutic potential of oncolytic vaccinia virus.

@en

P2093

Steve H Thorne

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal.

Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Ligand-directed targeting of genes to the site of disease.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

P2888

s12026-011-8211-4

P304

286-293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12026-011-8211-4

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51455645

http://www.w3.org/2001/XMLSchema#string

P698

21717084

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus